J. Goldman & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

J. Goldman & Co’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.75M	Buy	19,100 +11,100	+139%	+$3.35M	0.15%	183
2026 Q1	$2.65M	Sell	8,000 -13,500	-63%	-$4.59M	0.08%	276
2025 Q4	$8.55M	Buy	+21,500	New	+$9.52M	0.23%	123
2025 Q2	–	Sell	-36,000	Closed	-$9.72M	–	451
2025 Q1	$9.72M	Buy	+36,000	New	+$9.25M	0.24%	132
2023 Q1	–	Sell	-6,800	Closed	-$1.62M	–	352
2022 Q4	$1.62M	Buy	+6,800	New	+$1.45M	0.08%	191
2018 Q2	–	Sell	-26,500	Closed	-$3.16M	–	350
2018 Q1	$3.16M	Buy	+26,500	New	+$3.42M	0.13%	172

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's ALNY Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 38,698 shares worth $11.6M. The stake represents 0.3% of the portfolio and ranks #92 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in ALNY as recently as Q4 2025.

J. Goldman & Co first reported a position in ALNY in Q1 2025 and has held it in 3 quarters since. The position peaked at $20M in Q1 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

J. Goldman & Co held 38,698 shares of Alnylam Pharmaceuticals worth $11.6M as of Q2 2026.
Alnylam Pharmaceuticals was a new J. Goldman & Co position in Q2 2026.
Alnylam Pharmaceuticals made up 0.3% of J. Goldman & Co's portfolio in Q2 2026, its #92 holding.
J. Goldman & Co first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
J. Goldman & Co's Alnylam Pharmaceuticals position peaked at $20M in Q1 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.